Combination immunotherapy including OncoVEXmGMCSF creates a favorable tumor immune micro-environment in transgenic BRAF murine melanoma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combination immunotherapy including OncoVEXmGMCSF creates a favorable tumor immune micro-environment in transgenic BRAF murine melanoma
Authors
Keywords
-
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-01-09
DOI
10.1007/s00262-021-03088-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Distinguishing melanophages from tumor in melanoma patients treated with talimogene laherparepvec
- (2020) Claire Audrey-Bayan et al. MELANOMA RESEARCH
- Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer
- (2020) Eva Crespo-Rodriguez et al. Journal for ImmunoTherapy of Cancer
- Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study
- (2020) Sandra Huynh et al. Cancers
- Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
- (2020) Reinhard Dummer et al. NATURE MEDICINE
- Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
- (2019) Paolo Antonio Ascierto et al. NATURE MEDICINE
- Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
- (2019) Robert H. I. Andtbacka et al. Journal for ImmunoTherapy of Cancer
- Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series
- (2018) Lillian Sun et al. Journal for ImmunoTherapy of Cancer
- Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- The Role of Oncolytic Viruses in the Treatment of Melanoma
- (2018) Claire-Audrey Y. Bayan et al. Current Oncology Reports
- MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation
- (2018) Praveen K. Bommareddy et al. Science Translational Medicine
- Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma
- (2016) Praveen K. Bommareddy et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations
- (2016) Katrina Meeth et al. Pigment Cell & Melanoma Research
- Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers
- (2016) Claud Grigg et al. SEMINARS IN ONCOLOGY
- BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress
- (2015) Victoria Roulstone et al. MOLECULAR THERAPY
- Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors
- (2014) Allison Ackerman et al. CANCER
- BRAF V600E Cooperates with PI3K Signaling, Independent of AKT, to Regulate Melanoma Cell Proliferation
- (2014) Jillian M. Silva et al. MOLECULAR CANCER RESEARCH
- The role of BRAF V600 mutation in melanoma
- (2012) Paolo A Ascierto et al. Journal of Translational Medicine
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
- (2011) James S. Wilmott et al. CLINICAL CANCER RESEARCH
- Optimized PCR-based Detection of Mycoplasma
- (2011) Paige L. Dobrovolny et al. Jove-Journal of Visualized Experiments
- Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
- (2010) A. Boni et al. CANCER RESEARCH
- Herpes simplex virus oncolytic vaccine therapy in melanoma
- (2010) Shanthi Sivendran et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma
- (2009) Howard L. Kaufman et al. ANNALS OF SURGICAL ONCOLOGY
- BrafV600E cooperates with Pten loss to induce metastatic melanoma
- (2009) David Dankort et al. NATURE GENETICS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started